Personalized pharmacotherapy for Type 2 diabetes mellitus

被引：9
作者：
Sathananthan, Airani [1 ]
Vella, Adrian [1 ]
机构：
[1] Mayo Clin, Div Endocrinol Diabet & Metab, Dept Med, Rochester, MN 55905 USA
来源：
PERSONALIZED MEDICINE | 2009年 / 6卷 / 04期
关键词：
OCT; 1; pharmacogenetics; sulfonylureas; TCF7L2; Type 2 diabetes mellitus; DIPEPTIDYL PEPTIDASE-4 INHIBITORS; INSULIN-SECRETION; SECONDARY FAILURE; INCREASED RISK; TCF7L2; GENE; VARIANT; SULFONYLUREA; THERAPY; POLYMORPHISMS; PIOGLITAZONE;
D O I：
10.2217/PME.09.3
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Genome-wide linkage and association studies have been applied to Type 2 diabetes in order to discover common genetic variation that contributes to disease risk. While there has been progress in understanding how genetic variation predisposes to diabetes, there is less of an understanding of how genetics can alter drug response. The hope is that in the future, pharmacogenetics can help guide the treatment of diabetes, thereby improving control while minimizing side effects in a large group of patients.
引用
收藏
页码：417 / 422
页数：6
相关论文
共 36 条
  • [21] Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials
    Madsbad, Sten
    Krarup, Thure
    Deacon, Carolyn F.
    Holst, Jens J.
    [J]. CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE, 2008, 11 (04) : 491 - 499
  • [22] Extension of type 2 diabetes genome-wide association scan results in the Diabetes Prevention Program
    Moore, Allan F.
    Jablonski, Kathleen A.
    McAteer, Jarred B.
    Saxena, Richa
    Pollin, Toni I.
    Franks, Paul W.
    Hanson, Robert L.
    Shuldiner, Alan R.
    Knowler, William C.
    Altshuler, David
    Florez, Jose C.
    [J]. DIABETES, 2008, 57 (09) : 2503 - 2510
  • [23] Genetic susceptibility to type 2 diabetes and implications for antidiabetic therapy
    Moore, Allan F.
    Florez, Jose C.
    [J]. ANNUAL REVIEW OF MEDICINE, 2008, 59 : 95 - 111
  • [24] Thiazolidinedione use, fluid retention, and congestive heart failure
    Nesto, RW
    Bell, D
    Bonow, RO
    Fonseca, V
    Grundy, SM
    Horton, ES
    Le Winter, M
    Porte, D
    Semenkovich, CF
    Smith, S
    Young, LH
    Kahn, R
    [J]. DIABETES CARE, 2004, 27 (01) : 256 - 263
  • [25] Variation in TCF7L2 influences therapeutic response to sulfonylureas -: A GoDARTs study
    Pearson, Ewan R.
    Donnelly, Louise A.
    Kimber, Charlotte
    Whitley, Adrian
    Doney, Alex S. F.
    McCarthy, Mark I.
    Hattersley, Andrew T.
    Morris, Andrew D.
    Palmer, Colin N. A.
    [J]. DIABETES, 2007, 56 (08) : 2178 - 2182
  • [26] Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations
    Pearson, Ewan R.
    Flechtner, Isabelle
    Njolstad, Pal R.
    Malecki, Maciej T.
    Flanagan, Sarah E.
    Larkin, Brian
    Ashcroft, Frances M.
    Klimes, Iwar
    Codner, Ethel
    Iotova, Violeta
    Slingerland, Annabelle S.
    Shield, Julian
    Robert, Jean-Jacques
    Holst, Jens J.
    Clark, Penny M.
    Ellard, Sian
    Sovik, Oddmund
    Polak, Michel
    Hattersley, Andrew T.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (05) : 467 - 477
  • [27] Impaired glucagon-like peptide-1-induced insulin secretion in carriers of transcription factor 7-like 2 (TCF7L2) gene polymorphisms
    Schaefer, S. A.
    Tschritter, O.
    Machicao, F.
    Thamer, C.
    Stefan, N.
    Gallwitz, B.
    Holst, J. J.
    Dekker, J. M.
    t'Hart, L. M.
    Nijpels, G.
    van Haeften, T. W.
    Haering, H. U.
    Fritsche, A.
    [J]. DIABETOLOGIA, 2007, 50 (12) : 2443 - 2450
  • [28] The Arg972 variant in insulin receptor substrate-1 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes
    Sesti, G
    Marini, MA
    Cardellini, M
    Sciacqua, A
    Frontoni, S
    Andreozzi, F
    Irace, C
    Lauro, D
    Gnasso, A
    Federici, M
    Perticone, F
    Lauro, R
    [J]. DIABETES CARE, 2004, 27 (06) : 1394 - 1398
  • [29] The E23K variant of KCNJ11 encoding the pancreatic β-cell adenosine 5′-triphosphate-sensitive potassium channel subunit Kir6.2 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes
    Sesti, Giorgio
    Laratta, Emanuela
    Cardellini, Marina
    Andreozzi, Francesco
    Del Guerra, Silvia
    Irace, Concetta
    Gnasso, Agostino
    Grupillo, Maria
    Lauro, Renato
    Hribal, Marta Letizia
    Perticone, Francesco
    Marchetti, Piero
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2006, 91 (06) : 2334 - 2339
  • [30] THE EFFECT OF LONG-TERM INTENSIFIED INSULIN-TREATMENT ON THE DEVELOPMENT OF MICROVASCULAR COMPLICATIONS OF DIABETES-MELLITUS
    REICHARD, P
    NILSSON, BY
    ROSENQVIST, U
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (05) : 304 - 309
1234